![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Genotypic Analysis of the HIV-1 gp120 V3 Loop for Treatment-Experienced Patients Enrolled Into the MOTIVATE Studies and Who Received Maraviroc + Optimized Background Therapy
|
|
|
Reported by Jules Levin
CROI 2010 SF, Feb 16-19
Marilyn Lewis1, Paul Simpson1, Christophe Delogne1, John Sullivan1, Hernan Valdez3, Richard Harrigan2 and Mike Westby1
1Pfizer Global R&D, Sandwich, Kent, UK; 2BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 3Pfizer Inc. New York, NY
![](../images/030310/030310-9/image002.gif)
![](../images/030310/030310-9/image004.gif)
![](../images/030310/030310-9/image006.gif)
![](../images/030310/030310-9/image008.gif)
![](../images/030310/030310-9/image010.gif)
![](../images/030310/030310-9/image012.gif)
![](../images/030310/030310-9/image014.gif)
![](../images/030310/030310-9/image016.gif)
![](../images/030310/030310-9/image018.gif)
![](../images/030310/030310-9/image020.gif)
![](../images/030310/030310-9/image022.gif)
![](../images/030310/030310-9/image024.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|